Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
OncoSil Medical Ltd ( (AU:OSL) ) just unveiled an announcement.
OncoSil Medical Ltd has announced the appointment of Dr. Thomas Duthy as a Non-Executive Director, effective July 11, 2025. Dr. Duthy brings over 21 years of experience in financial markets, corporate development, and board-level roles in the healthcare and life sciences sectors. His appointment comes as the company is experiencing strong clinical momentum with its PANCOSIL and TRIPP-FFX trials and expanding its treatment footprint across Europe. Dr. Duthy’s expertise in capital markets and strategic transactions is expected to be invaluable as OncoSil continues to scale its global presence and drive shareholder value.
More about OncoSil Medical Ltd
OncoSil Medical Ltd is a company that specializes in developing cancer treatment devices, specifically the OncoSil™ brachytherapy device. This device is a pivotal component in the treatment of locally advanced unresectable pancreatic cancer, a condition with a poor prognosis and typically diagnosed at a later stage. The OncoSil™ device has received breakthrough device designation in the EU, UK, and US, and is approved for sale in over 30 countries, including the European Union, United Kingdom, Türkiye, and Israel.
Average Trading Volume: 40,604
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$17.7M
Learn more about OSL stock on TipRanks’ Stock Analysis page.